Abstract
SummaryIn order to assess the therapeutic efficacy of amisulpride in dysthymic disorder, two randomised double-blind trials were conducted in France. Both studies included outpatients meeting DSM-III-R criteria for primary dysthymia. Cases of double depressed patients with a mild or moderate major depressive episode superimposed to dysthymia were also eligible. The first study of a three-month duration compared amineptine (200 mg/day) to amisulpride (50 mg/day) and placebo. The second study of a six-month duration compared the therapeutic effects of imipramine (100 mg/day) to amisulpride (50 mg/day) and placebo. Results of the intention to treat analysis and of the end-point analysis were compelling and very similar: significant differences were demonstrated for all primary criteria between amisulpride and placebo and between imipramine and placebo but not between amisulpride and imipramine. For both primary criteria and the responder rate (CGI), statistically significant differences were evidenced between amisulpride and placebo and amineptine and placebo. The same differences were evidenced for SANS subscores. Beneficial effects of low doses of amisulpride in chronic depressive condition can therefore be discussed.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health
Reference21 articles.
1. The treatment of dysthymies with a dopaminergic presynaptic blocker;Lecrubier;Neuropsychopharmacology,1994
2. Interrelations entre les neuromédiateurs impliqués dans la dépression et les antidépresseurs;Tassin;Encéphale,1994
3. Dysthymia and depressive disorders: dopamine hypothesis
4. Randomized double-blind study of fluoxetine versus placebo in treatment of dysthymia;Hellerstein;Am J Psychiatry,1993
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献